Flora Peyvandi Introduces Breakthrough Protease-Resistant ADAMTS13 Enhancing VWF Regulation in Thrombotic Disorders
A new study published in Blood Advances by Prof. Flora Peyvandi and colleagues presents a study about a bioengineered, protease-resistant form of ADAMTS13, designed to enhance resistance to proteolytic degradation without compromising its functional regulation of von Willebrand factor (VWF)-posted on X:
“Mortality, diagnosis, and etiology of disseminated intravascular coagulation – A systematic review and meta-analysis: Communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.”
Recombinant ADAMTS13 has shown therapeutic potential in thrombotic disorders such as heritable TTP and is under investigation for use in acquired TTP and sickle cell disease. However, its susceptibility to degradation by proteases like plasmin limits its efficacy, especially under thrombo-inflammatory conditions. This study introduces protease-resistant ADAMTS13 variants—specifically modified in linker regions—that retain full VWF-cleaving function under flow. These stabilized forms resist cleavage by thrombin, FXIa, kallikrein, and neutrophil-derived enzymes, without compromising antithrombotic activity. The findings suggest that protease-resistant ADAMTS13 may enhance therapeutic durability in TTP and broaden its use in thrombosis-related diseases such as ischemic stroke and myocardial infarction.
Title: Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation
Autors: Veronica DeYoung, Rex Huang, Hasam Madarati, Rida Malik, Peter Andrisani, Cherie Teney, Colin A. Kretz
Similar exciting news can be found in Hemostasis Today.
-
Oct 23, 2025, 06:03Melanie Daniel: Wonderful Presentation on Emicizumab by Mickael Rosa at ECTH
-
Oct 22, 2025, 06:17We Will Continue to Raise Awareness and Remind Rveryone That Donating Blood Means Saving Lives - Yeolyan Hematology and Oncology Center
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 23, 2025, 06:48Omid Seidizadeh Shares Deep Molecular Modeling and Mechanistic Insights into Type 2A VWD
-
Oct 23, 2025, 06:45Mélanie Roussel on D-Dimer Thresholds for Diagnosis of Pulmonary Embolism
-
Oct 23, 2025, 06:28Ramya Ramakrishnan on IDA Association with Depression
-
Oct 23, 2025, 06:07Cedric Hermans: Von Willebrand Disease Diagnosis - From Complexity to Simplicity
-
Oct 23, 2025, 05:45Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 23, 2025, 06:52Louise Bannon: Thrilled to Witness The Incredible Reach of This Year's World Thrombosis Day!
-
Oct 23, 2025, 06:50Caitlin Raymond to Speak at The 11th Annual Bloodless Medicine and Surgery Society Conference
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025
-
Oct 22, 2025, 10:32Lynn Malec - The New Director of the CCBD and Pharmacy at Children's Wisconsin
-
Oct 22, 2025, 09:41Deanna Joseph: Feeling Inspired and Deeply Grateful After Attending the 2025 HTRS SEARCH Workshop